| Literature DB >> 36013279 |
Sofia Galvão Feronato1, Maria Luiza Matos Silva2, Rafael Izbicki2, Ticiana D J Farias1,3, Patrícia Shigunov1, Bruno Dallagiovanna1, Fabio Passetti1, Hellen Geremias Dos Santos1.
Abstract
Amyotrophic lateral sclerosis (ALS) is a multi-system neurodegenerative disease that affects both upper and lower motor neurons, resulting from a combination of genetic, environmental, and lifestyle factors. Usually, the association between single-nucleotide polymorphisms (SNPs) and this disease is tested individually, which leads to the testing of multiple hypotheses. In addition, this classical approach does not support the detection of interaction-dependent SNPs. We applied a two-step procedure to select SNPs and pairwise interactions associated with ALS. SNP data from 276 ALS patients and 268 controls were analyzed by a two-step group LASSO in 2000 iterations. In the first step, we fitted a group LASSO model to a bootstrap sample and a random subset of predictors (25%) from the original data set aiming to screen for important SNPs and, in the second step, we fitted a hierarchical group LASSO model to evaluate pairwise interactions. An in silico analysis was performed on a set of variables, which were prioritized according to their bootstrap selection frequency. We identified seven SNPs (rs16984239, rs10459680, rs1436918, rs1037666, rs4552942, rs10773543, and rs2241493) and two pairwise interactions (rs16984239:rs2118657 and rs16984239:rs3172469) potentially involved in nervous system conservation and function. These results may contribute to the understanding of ALS pathogenesis, its diagnosis, and therapeutic strategy improvement.Entities:
Keywords: amyotrophic lateral sclerosis; genome-wide association studies; group LASSO regularization; pairwise interaction; single-nucleotide polymorphisms
Year: 2022 PMID: 36013279 PMCID: PMC9410070 DOI: 10.3390/jpm12081330
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1Frequency of non-zero estimated coefficient for the seven most frequently selected variants in the first step group LASSO regularization.
Figure 2Distribution of the estimated coefficients for the seven most frequently selected variants in the first step group LASSO regularization.
Non-adjusted odds ratio for amyotrophic lateral sclerosis according to the prioritized single-nucleotide polymorphisms in the first step of the group LASSO regularization.
| Variant | Total | ALS | OR | 95%CI | |
|---|---|---|---|---|---|
| rs16984239 (A) | |||||
| 0 | 378 | 165 (0.44) | reference | ||
| 1 | 153 | 104 (0.68) | 2.74 | 1.85; 4.10 | <0.001 |
| 2 | 13 | 7 (0.54) | 1.51 | 0.49; 4.76 | 0.469 |
| rs1037666 (C) | |||||
| 0 | 247 | 151 (0.61) | reference | ||
| 1 | 242 | 100 (0.41) | 0.45 | 0.31; 0.64 | <0.001 |
| 2 | 55 | 25 (0.45) | 0.53 | 0.29; 0.95 | 0.035 |
| rs10459680 (T) | |||||
| 0 | 281 | 118 (0.42) | reference | ||
| 1 | 230 | 142 (0.62) | 2.23 | 1.56; 3.19 | <0.001 |
| 2 | 33 | 16 (0.48) | 1.30 | 0.63; 2.69 | 0.477 |
| rs4552942 (C) | |||||
| 0 | 277 | 165 (0.60) | reference | ||
| 1 | 226 | 090 (0.40) | 0.45 | 0.31; 0.64 | <0.001 |
| 2 | 41 | 21 (0.51) | 0.71 | 0.37; 1.38 | 0.313 |
| rs10773543 (G) | |||||
| 0 | 230 | 142 (0.62) | reference | ||
| 1 | 261 | 109 (0.42) | 0.44 | 0.31; 0.64 | <0.001 |
| 2 | 53 | 25 (0.47) | 0.55 | 0.30; 1.01 | 0.054 |
| rs2241493 (C) | |||||
| 0 | 345 | 198 (0.57) | reference | ||
| 1 | 180 | 067 (0.37) | 0.44 | 0.30; 0.64 | <0.001 |
| 2 | 19 | 11 (0.58) | 1.02 | 0.40; 2.70 | 0.966 |
| rs1436918 (A) | |||||
| 0 | 129 | 061 (0.47) | reference | ||
| 1 | 288 | 171 (0.59) | 1.63 | 1.07; 2.48 | 0.022 |
| 2 | 127 | 44 (0.35) | 0.59 | 0.36; 0.98 | 0.040 |
Genome position and genomic context of the selected single-nucleotide polymorphisms.
| SNP | Chr:Location | Gene | Consequence | Phenotype | Citation |
|---|---|---|---|---|---|
|
| |||||
| rs16984239 | 2:18053180 | - | intergenic | ALS | [ |
| rs1037666 | 1:240195185 | FMN2 | intronic | ALS | [ |
| rs10459680 | 15:93138241 | LOC101927025 | intronic | ALS | [ |
| rs4552942 | 8:135862080 | LINC02055 | intronic | ALS; core binding factor acute myeloid leukemia | [ |
| rs10773543 | 12:128439181 | TMEM132C | intronic | ALS | [ |
| rs2241493 | 15:31070149 | TRPM1 | missense | Congenital stationary night blindness, type 1C | [ |
| rs1436918 | 15:34644720 | LOC390569 | regulatory genomic region | ALS | [ |
|
| |||||
| rs2118657 | 3:165864723 | - | intergenic | - | - |
| rs3172469 | 3:187741300 | BCL6 | intronic | Myeloma; non-Hodgkin lymphoma | [ |
Figure 3Distribution of the estimated coefficients for the two pairwise interactions selected in the second step group LASSO regularization.
Non-adjusted odds ratio for amyotrophic lateral sclerosis according to the selected pairwise interactions in the second step group LASSO regularization.
| Variant | Total | ALS | OR | 95%CI | |
|---|---|---|---|---|---|
| rs2118657 (T) = 0 | |||||
| rs16984239 (A) = 0 | 189 | 61 (0.32) | reference | ||
| rs16984239 (A) = 1 | 83 | 55 (0.66) | 4.12 | 2.38; 7.13 | <0.001 |
| rs16984239 (A) = 2 | 7 | 6 (0.86) | 12.59 | 1.48; 106.89 | 0.020 |
| rs2118657 (T) = 1 | |||||
| rs16984239 (A) = 0 | 162 | 93 (0.57) | reference | ||
| rs16984239 (A) = 1 | 64 | 46 (0.72) | 1.90 | 1.01; 3.55 | 0.046 |
| rs16984239 (A) = 2 | 6 | 1 (0.17) | 0.15 | 0.02; 1.30 | 0.085 |
| rs2118657 (T) = 2 | |||||
| rs16984239 (A) = 0 | 27 | 11 (0.41) | reference | ||
| rs16984239 (A) = 1 | 6 | 3 (0.50) | 1.45 | 0.25; 8.58 | 0.679 |
| rs16984239 (A) = 2 | - | - | - | - | - |
| rs3172469 (G) = 0 | |||||
| rs16984239 (A) = 0 | 200 | 65 (0.33) | reference | ||
| rs16984239 (A) = 1 | 83 | 55 (0.66) | 4.08 | 2.37; 7.02 | <0.001 |
| rs16984239 (A) = 2 | 8 | 4 (0.50) | 2.08 | 0.50; 8.57 | 0.312 |
| rs3172469 (G) = 1 | |||||
| rs16984239 (A) = 0 | 150 | 84 (0.56) | reference | ||
| rs16984239 (A) = 1 | 63 | 45 (0.71) | 1.96 | 1.04; 3.71 | 0.037 |
| rs16984239 (A) = 2 | 5 | 3 (0.60) | 1.18 | 0.19; 7.26 | 0.859 |
| rs3172469 (G) = 2 | |||||
| rs16984239 (A) = 0 | 28 | 61 (0.47) | reference | ||
| rs16984239 (A) = 1 | 7 | 4 (0.57) | 1.00 | 0.19; 5.33 | 0.999 |
| rs16984239 (A) = 2 | - | - | - | - | - |